Janvier Labs is pleased to support the next generation of translational research with the addition of several sophisticated models to their catalog. Engineered to deliver enhanced physiological relevance, these sophisticated tools – including the B6h GLP1R, B6h CA4, B6h SORT1, NXG MHC DKO, and NXG FcClarity – enable scientists to assess human-targeted therapeutics with exceptional accuracy.
B6h GLP1R
The B6h GLP1R mouse features human glucagon-like peptide-1 receptor expression under native regulatory control on a C57BL/6 genetic background. This model facilitates accurate assessment of GLP-1R-specific agonists, biased signaling compounds, and antibody therapeutics designed for human targets. It supports translational studies in metabolic conditions including obesity, diabetes, and cardiovascular-metabolic disorders.
B6h CA4
The B6h CA4 model incorporates the human carbonic anhydrase IV gene in place of its mouse equivalent. This humanized platform allows researchers to study species-dependent pharmacological responses, antibody recognition, and toxicity profiles of CA4-directed therapeutics. Bred on a consistent C57BL/6 background, it delivers reliable outcomes in kidney, lung, and vascular research settings.
B6h SORT1
The B6h SORT1 mouse carries the human sortilin-1 receptor gene substituted for the native sequence. With SORT1’s central role in lipoprotein processing and cardiovascular pathology, this platform supports testing of human-targeted biologics and genetic intervention approaches. It proves especially valuable for studies in atherosclerosis, lipid regulation, and cardiovascular drug development.
NXG MHC DKO
Built on the NXG genetic platform, the NXG MHC DKO eliminates both mouse MHC class I and class II molecules. This double deletion enhances human immune cell transplantation success by limiting host antigen recognition. The model is tailored for sophisticated humanization protocols in cancer immunology and cellular therapy investigations.
NXG FcClarity
Engineered from the NXG foundation, NXG FcClarity is modified to suppress mouse Fc receptor engagement. This refinement eliminates off-target human IgG binding, clarifying therapeutic antibody performance and toxicology assessment. The platform strengthens translational confidence in antibody therapeutics and immuno-oncology research.
Through the addition of these advanced platforms to your research toolkit, Janvier Labs reinforces its dedication to providing superior preclinical solutions. From metabolic science to immuno-oncology and antibody engineering, Janvier Labs looks forward to supporting your 2026 research objectives with these high-fidelity translational systems.